Prescient Surgical raises $10M for CleanCision therapy: 3 notes

Prescient Surgical raised $10 million in series B funding.

Here are three things to know:

1. Baxter Ventures, the venture investment arm of Baxter International, led the funding round. Other investors included Summation Health, CWC HealthTech Advisors and Stanford-StartX Fund.

2. The funding will accelerate the availability of Prescient Surgical's CleanCision therapy, which targets the sources of surgical site infection.

3. SSI, particularly in abdominal surgery, poses a significant threat to patient safety. An estimated 15 percent of patients undergoing high-risk abdominal surgery will develop an SSI.